Evaluation of the Evolution of Imaging Markers of Cartilage Degradation in Patients With Knee Osteoarthritis Receiving DROGLICAN

• Status: Unknown status
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

A previous multicenter trial led by Bioiberica S.A. has confirmed the efficacy and safety of DROGLICAN for the treatment of osteoarthritis (OA) in patients with severe pain. The MOVES study was a phase IV, double blind, randomized and non-inferiority trial to compare the efficacy and safety of a fixed dose combination of glucosamine hydrochloride (GH) + chondroitin sulfate (CS) (DROGLICAN) versus celecoxib in patient with symptomatic knee OA with moderate to severe pain. This study concluded that both drugs reduced the WOMAC Pain subscale by 50% without significant difference between groups. Further, there was no difference in all secondary outcomes assessing patient's pain, functional capacity, stiffness, inflammation, joint swelling, effusion, and overall quality of life.

This new exploratory trial is aimed to evaluate the beneficial effect of DROGLICAN on the good health of the cartilage of patients suffering of knee osteoarthritis as revealed by qualitative assessment of cartilage biochemical composition in vivo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bioiberica
• Collaborator: Artialis
• Treatments: Acetaminophen; Cyclooxygenase 2 Inhibitors

Criteria

Inclusion Criteria:

• Femorotibial knee OA (Uni- or bilateral)

• Responding to clinical and radiological criteria of American College of Rheumatology (ACR)

• Symptomatic for more than 6 months in the most painful knee

• Radiological K&L grade II-III in radiographs from less than 12 months

• Moderate-to-severe knee pain: knee pain score evaluated on Visual Analogue Scale (VAS) (0-100) ≥ 40 over the last 24 hours at the inclusion visit (the most painful knee is considered)

• Able to follow the instructions of the study

• Having signed an informed consent

Exclusion Criteria:

Related to the OA pathology

• Recent trauma (< 1 month) of the knee responsible of the symptomatic knee

• Concurrent articular disease interfering with the evaluation of OA and/or pain such as articular dysplasia, aseptic osteonecrosis, acromegaly, Paget's disease, hemophilia, hemochromatosis, chondromatosis, villonodular synovitis of the knee, seronegative spondyloarthropathy, rheumatoid arthritis, gouty arthritis , infectious arthritis, radiculalgia in the lower limbs, arteritis, etc.

• Radiological K&L grade I or IV

• Prosthesis in the target knee

Related to treatments

• Analgesics to manage OA knee pain 24h before inclusion visit

• Corticosteroids injection in the target knee in the month preceding inclusion

• Hyaluronan injection in the target knee in the last 6 months

• Oral corticotherapy ≥ 5mg/day in the last 3 months

• Symptomatic slow-acting drugs (SYSADs) treatment (Chondroitin, diacerein, glucosamine, soy and avocado unsaponifiables) in the last 3 months

• An anticipated need for any OA related medication for the duration of the trial (Corticosteroids or hyaluronan injection, Oral corticotherapy, Arthroscopy, analgesics other than the authorized rescue treatments) which are forbidden during the trial

• Arthroscopy in the last 6 months

• Patients with known allergy to CS, GH, or intolerance to rescue treatment (Paracetamol and NSAIDs)

• Patients with allergy to shellfish

Related to associated diseases

• Severe and uncontrolled diseases (liver or renal failure, lung/heart severe disease, tumor, HIV….)

• Anticipated need for any surgical or other invasive procedure during the trial including prosthesis in the target knee Related to patients

• Artialis (study coordinator) or Bioiberica (Sponsor) 's employees

• Participation to a therapeutic clinical trial in the last 3 months

• Under guardianship or judicial protection

• Pregnancy, breastfeeding, planned conception

• Women without menopause or tubal ligation and without contraception

Related to MRI

• Unable to receive gadopentetate contrast agent injection because of contraindications:

• Acute or chronic severe renal insufficiency (a glomerular filtration rate < 30 mL/min/1.73m2); or

• Acute renal insufficiency of any severity due to the hepato-renal syndrome or in the peri-operative liver transplantation period.

• Known anaphylactic reactions to Gadolinium or related substances

• Risk groups for MRI scanning due to magnetic field or contrast agent: Metal in body:

Pacemaker / Automatic Implantable Cardioverter Defibrillators / Implantable Cardioverter Defibrillators (coronary defibrillator), Nervus vagus stimulator, Artificial heart valve (depending on type), Metal clips on cerebral arteries or veins, Metal particles in eye, Port-a-cath, Metal stents, Hydrocephalic pump / insulin pump, Metal implants; f/e screws, prostheses, piercings.

• Claustrophobia, or serious mobility problem (Parkinson, tremors)